Progenra Scientists Make Advances in Parkinson’s Disease “New Mode of Action for Parkinson’s Disease Drug, a Conceptual Shift in Neurodegeneration”
June 12, 2026 MALVERN, PA. Progenra Inc. announced continued progress in the development of its small-molecule activators of PINK1 kinase, a key regulator of mitochondrial quality control and cellular energy homeostasis. The company is advancing novel therapeutics designed to activate the PINK1/Parkin signaling pathway, which plays a critical role in the repair and clearance of damaged […]
Progenra Invited to Speak at Symposium “From Mechanisms to Therapeutic Insight in Neurodegeneration”
Nov 20, 2025, 10:30 AM Eastern Daylight Time Progenra Drug Offers Hope for Therapy for Parkinson’s and Alzheimer’s disease MALVERN, Pa. (Business Wire) — Neurodegenerative diseases present a global health challenge. Aggregation of proteins in neurons is the main cause of several neurodegenerative disorders. Tau protein aggregates for Alzheimer’s disease and alpha synuclein aggregates for […]
A New Parkinson’s Disease Drug Function in Inherited form of Parkinson’s Disease Breakthrough Discovery Offers Hope for Precision Therapy in Mitochondrial Dysfunction Disorders
Malvern, PA, Progenra Inc — June 16th, 2025 — Parkinson’s disease is the second most prevalent neurodegenerative disease and presents a global health challenge, effecting 10 million people world-wide. About 90,000 people are diagnosed with Parkinson’s disease in US every year. About 1.2 million people will suffer from Parkinson’s disease in US by year 2030, […]
Progenra Scientists Develop Technology to Discover Targeted Protein Degradation Drugs, PROTACs and Molecular Glues
Malvern, PA — Progenra, Inc. a biotech company focused neurodegenerative drugs is pleased to announce the development of a new technology that will facilitate rapid discovery of drugs that work via Targeted Protein Degradation (TPD). A wave new drug candidate, called PROTACs or molecular glue drugs are emerging from pharmaceutical and biotech companies that work […]